Cushing syndrome

Relacorilant

Relacorilant is a selective glucocorticoid receptor modulator being investigated for the treatment of endogenous hypercortisolism. One phase 2 trial evaluated the efficacy and safety of relacorilant in patients with endogenous Cushing syndrome and found that it improved clinical hypertension and hyperglycaemia parameters.[113]Pivonello R, Bancos I, Feelders RA, et al. Relacorilant, a selective glucocorticoid receptor modulator, induces clinical improvements in patients with Cushing syndrome: results from a prospective, open-label phase 2 study. Front Endocrinol (Lausanne). 2021 Jul 14;12:662865. https://pmc.ncbi.nlm.nih.gov/articles/PMC8317576 http://www.ncbi.nlm.nih.gov/pubmed/34335465?tool=bestpractice.com ​ Relacorilant has received orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of hypercortisolism, and the agency is currently reviewing the drug for approval.